Welcome to the November edition of the ADNeT newsletter!
I’m thrilled to share that the ADNeT Registry is one of the two inaugural recipients of the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) grant, alongside the Netherlands’ Aboard Cohort. This grant will support the ADNeT Registry in collecting clinical and safety data on Alzheimer’s disease treatments, once approved in Australia, and tracking long-term outcomes in real-world setting. ALZ-NET is led by the U.S. Alzheimer’s Association.
We are also pleased to announce two new partners have joined ADNeT- the Bionics Institute, an internationally recognised medical research institute and the Dementia Australia Research Foundation (DARF). These new partnerships allow for vital knowledge sharing, expand capacity and reach for impactful research, and collectively address the growing prevalence of dementia in Australia with a more powerful, united approach.
ADNeT has been active in the media with research led by ADNeT Director Professor Christopher Rowe and Florey researchers showing promising results for a new blood test for accurate and effective diagnosis of Alzheimer’s disease. The research received media coverage in the Herald Sun, Seven News, and on radio stations around Australia.
Additionally, ADNeT was also mentioned in the Herald Sun expressing disappointment at the Therapeutic Goods Administration’s decision to reject the use of lecanemab in Australia.
I trust you’ll find this month’s newsletter both informative and engaging! You can read it in full here.